FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809975480> ?p ?o ?g. }

• W2809975480 abstract "Objective: To determine whether onabotulinumtoxinA therapy is effective in the treatment of New Daily Persistent Headache (NDPH). Background: New Daily Persistent Headache (NDPH) is a difficult to treat headache syndrome resistant to both conventional and unconventional headache therapies. NDPH was excluded in the registration trials for onabotunlinumtoxinA (onabot) in chronic migraine. Apart from case reports supporting its benefit, little is known about its therapeutic value in NDPH. Design/Methods: We performed a single center, retrospective chart review of patients with a diagnosis of NDPH who received onabot treatment over a 30 month period. Measures of interest were headache frequency and headache severity. After excluding patients seen at the Cleveland Clinic outside of the Headache Center, patients with missing data at baseline, patients that no longer had daily headache, and patients without valid data at any follow-up time point, there were 19 patients for frequency analysis and 14 for severity analysis. All patients had received the FDA-approved PREEMPT Protocol. Results: A decrease in headache frequency was noted in 8/16 (50.0%) patients at 6 months and 7/11 (63.6%) at 12 months. Using mixed effect logistic regression models, which account for loss-to-follow-up, the estimated percentage improving at 6 months was 49.7%, and at 12 months, 58.3%. Headache severity improved in 5/10 (50.0%) of patients at 6 months and in 7/9 (77.8%) at 12 months. Using mixed effect logistic regression models, the estimated percentage improving at 6 months was 50.0%, and at 12 months, 78.1%. Conclusions: Most therapies are unable to break the unremitting course of NDPH. In our investigation, at 1 year (3–4 cycles of onabot treatment), approximately half of the patients treated showed a reduction in headache frequency and approximately 75% demonstrated some improvement in headache severity. OnabotulinumtoxinA may be a reasonable choice in the treatment of NDPH, but a randomized controlled study should be the next step. Disclosure: Dr. Ali has nothing to disclose. Dr. Kriegler has received research support from Allergan. Dr. Tepper has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alder, Allergan, Amgen, ATI, Avanir, BioVison, Charleston Laboratories, Dr. Reddy’s, electroCore, eNeura, Eli Lilly, GLG, Guidepoint Global, Kimberly-Clark, Pernix, Pfizer, Scion Neurostim, Supernus, Teva, Zosano. Dr. Vij has nothing to disclose." @default.
• W2809975480 created "2018-07-10" @default.
• W2809975480 creator A5035946333 @default.
• W2809975480 creator A5064341657 @default.
• W2809975480 creator A5083792693 @default.
• W2809975480 creator A5090612926 @default.
• W2809975480 date "2018-04-10" @default.
• W2809975480 modified "2023-09-24" @default.
• W2809975480 title "New Daily Persistent Headache (NDPH) & OnabotulinumtoxinA Therapy (P3.114)" @default.
• W2809975480 hasPublicationYear "2018" @default.
• W2809975480 type Work @default.
• W2809975480 sameAs 2809975480 @default.
• W2809975480 citedByCount "0" @default.
• W2809975480 crossrefType "journal-article" @default.
• W2809975480 hasAuthorship W2809975480A5035946333 @default.
• W2809975480 hasAuthorship W2809975480A5064341657 @default.
• W2809975480 hasAuthorship W2809975480A5083792693 @default.
• W2809975480 hasAuthorship W2809975480A5090612926 @default.
• W2809975480 hasConcept C126322002 @default.
• W2809975480 hasConcept C151956035 @default.
• W2809975480 hasConcept C167135981 @default.
• W2809975480 hasConcept C187212893 @default.
• W2809975480 hasConcept C2778541695 @default.
• W2809975480 hasConcept C2780073493 @default.
• W2809975480 hasConcept C2910587157 @default.
• W2809975480 hasConcept C3017906399 @default.
• W2809975480 hasConcept C44249647 @default.
• W2809975480 hasConcept C71924100 @default.
• W2809975480 hasConceptScore W2809975480C126322002 @default.
• W2809975480 hasConceptScore W2809975480C151956035 @default.
• W2809975480 hasConceptScore W2809975480C167135981 @default.
• W2809975480 hasConceptScore W2809975480C187212893 @default.
• W2809975480 hasConceptScore W2809975480C2778541695 @default.
• W2809975480 hasConceptScore W2809975480C2780073493 @default.
• W2809975480 hasConceptScore W2809975480C2910587157 @default.
• W2809975480 hasConceptScore W2809975480C3017906399 @default.
• W2809975480 hasConceptScore W2809975480C44249647 @default.
• W2809975480 hasConceptScore W2809975480C71924100 @default.
• W2809975480 hasLocation W28099754801 @default.
• W2809975480 hasOpenAccess W2809975480 @default.
• W2809975480 hasPrimaryLocation W28099754801 @default.
• W2809975480 hasRelatedWork W1516432178 @default.
• W2809975480 hasRelatedWork W1568416166 @default.
• W2809975480 hasRelatedWork W1980671619 @default.
• W2809975480 hasRelatedWork W2005993832 @default.
• W2809975480 hasRelatedWork W2013551983 @default.
• W2809975480 hasRelatedWork W2092822230 @default.
• W2809975480 hasRelatedWork W2133345144 @default.
• W2809975480 hasRelatedWork W2142509315 @default.
• W2809975480 hasRelatedWork W2212450248 @default.
• W2809975480 hasRelatedWork W2761354866 @default.
• W2809975480 hasRelatedWork W2766232839 @default.
• W2809975480 hasRelatedWork W2809431453 @default.
• W2809975480 hasRelatedWork W2886962068 @default.
• W2809975480 hasRelatedWork W2929053468 @default.
• W2809975480 hasRelatedWork W2961549905 @default.
• W2809975480 hasRelatedWork W2967904929 @default.
• W2809975480 hasRelatedWork W2980800551 @default.
• W2809975480 hasRelatedWork W3031175298 @default.
• W2809975480 hasRelatedWork W3166537990 @default.
• W2809975480 hasRelatedWork W3186302215 @default.
• W2809975480 hasVolume "90" @default.
• W2809975480 isParatext "false" @default.
• W2809975480 isRetracted "false" @default.
• W2809975480 magId "2809975480" @default.
• W2809975480 workType "article" @default.